Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes.
AIM
To examine the effect of oral diabetes medication on the risk of dementia in an elderly cohort with type 2 diabetes.


METHODS
This was a population-based cohort study using the Korean National Health Insurance claims data from 2002 to 2013. Elderly subjects (60 years of age or older) with and without type 2 diabetes were included; patients with new-onset type 2 diabetes were further divided into the oral diabetes medication group and no-medication group.


RESULTS
Among 278,290 patients with type 2 diabetes, 56,587 developed dementia (20.3%) over 11 years of follow-up. Type 2 diabetes was associated with a 1.69-fold increased risk of dementia (95% CI 1.66-1.72). Among patients with newly diagnosed type 2 diabetes, the risk of dementia was lower in the oral diabetes medication group than in the no-medication group (adjusted hazard ratio [aHR], 0.79; 95% CI 0.77-0.81). Lower risk of dementia was particularly noticeable in all of the combination therapy groups and especially lower in the combination therapy group treated with dipeptidyl peptidase 4 inhibitor (aHR 0.48, 95% CI 0.45-0.51).


CONCLUSION
Overall, the use of oral diabetes medication in type 2 diabetes patients significantly decreased the risk of dementia.
['Kim|Ju Young|JY|', 'Ku|Young Sook|YS|', 'Kim|Hyun Jeong|HJ|', 'Trinh|Nga Thi|NT|', 'Kim|Woorim|W|', 'Jeong|Bomi|B|', 'Heo|Tae Young|TY|', 'Lee|Myung Koo|MK|', 'Lee|Kyung Eun|KE|']
D000284:Administration, Oral D000368:Aged D000369:Aged, 80 and over D015331:Cohort Studies D003704:Dementia D003924:Diabetes Mellitus, Type 2 D054873:Dipeptidyl-Peptidase IV Inhibitors D004359:Drug Therapy, Combination D005260:Female D006801:Humans D007004:Hypoglycemic Agents D008297:Male D008875:Middle Aged D011379:Prognosis D012307:Risk Factors
Dementia Dipeptidyl peptidase 4 inhibitor Metformin Sulfonylurea Thiazolidinedione Type 2 diabetes mellitus